Orzeyful: NMPA Clears First OX2R Agonist for NT1

Key Takeaways

• NMPA approved Orzeyful (oveporexton) for NT1 in adolescents ≥16 and adults on 22 July 2026 — first oral OX2R agonist in China.
• Pivotal support: FirstLight (NCT06470828, n=168) and RadiantLight (NCT06505031, n=105), 12-week global Phase 3 studies across 19 countries.
• Takeda cites ~700,000 people with narcolepsy in China; NT1 is about 75–80% of cases; common adverse events include insomnia and urinary urgency/frequency.
• Outside China: FDA priority review (Breakthrough Therapy) and Japan Sakigake review are underway; more filings planned in 2026.

Orzeyful at a glance

Field	Detail
Brand / INN	Orzeyful / oveporexton (TAK-861)
Sponsor	Takeda Pharmaceutical Company Limited
Regulator / date	China NMPA — 22 July 2026
Indication	Narcolepsy type 1 (NT1), ages 16+ and adults
Mechanism	Oral orexin receptor 2 (OX2R)–selective agonist
Pivotal trials	FirstLight NCT06470828; RadiantLight NCT06505031
Other regions	FDA priority review; Japan Sakigake; more filings planned

What China’s NMPA cleared

In a 22 July 2026 Takeda China announcement, the company said NMPA approved Orzeyful for the treatment of narcolepsy type 1 in adolescents aged 16 years and older and adults. Oveporexton is described as the first oral OX2R-selective agonist approved in China and the only approved medicine there that treats NT1, shifting care from symptom-by-symptom agents toward a mechanism aimed at orexin deficiency.

Takeda estimates about 700,000 people in China have narcolepsy, with NT1 accounting for roughly 75–80% of cases. NT1 typically begins between ages 10 and 20 and can impair work, education, and driving safety; diagnostic delay often exceeds 10 years, the company notes. For competitive intelligence and medical affairs teams tracking NMPA China FDA drug approval pathways in 2026, this is a first-in-class neuroscience clearance rather than a me-too label expansion.

How do FirstLight and RadiantLight support the label?

Takeda says the China approval rests on the global Phase 3 FirstLight and RadiantLight program. FirstLight (NCT06470828) randomized 168 participants with NT1 to twice-daily 2 mg, 1 mg, or placebo for 12 weeks. RadiantLight (NCT06505031) randomized 105 participants to twice-daily 2 mg or placebo. Both studies used Maintenance of Wakefulness Test sleep latency as a primary wakefulness endpoint and evaluated Epworth Sleepiness Scale scores, weekly cataplexy rate, attention (PVT), and patient-reported function.

In a July 2025 Business Wire readout of the pivotal Phase 3 program, Takeda reported statistically significant improvements versus placebo across a broad NT1 symptom spectrum. The China package reiterates significance on excess daytime sleepiness and cataplexy endpoints, with a safety profile consistent with earlier data; the most common adverse events listed are insomnia, urinary urgency, and urinary frequency. Dose detail for the marketed China label should be taken from the Chinese package insert once distributed — this article does not invent mg strengths beyond the trial arms disclosed on ClinicalTrials.gov.

What does the OX2R mechanism change for NT1?

NT1 is driven by loss of orexin-producing neurons and collapsed orexin signaling. Oveporexton selectively stimulates OX2R to restore signaling, aiming to promote wakefulness and reduce REM-sleep–like phenomena such as cataplexy. That mechanism framing matters for BD and payers: prior symptomatic stacks (stimulants, antidepressants, oxybate-class agents) manage pieces of the phenotype; an OX2R agonist targets the causal pathway evaluated in the Phase 3 battery.

Earlier, the NEJM Phase 2b publication announced via Business Wire showed eight-week improvements in objective and subjective EDS and cataplexy versus placebo across doses. Phase 3 then scaled that signal globally before the China first approval. Teams comparing China first-launch patterns can juxtapose this neuroscience win with recent oncology and rare-disease NMPA moves such as NMPA’s ciprocopan PNH approval and iza-bren for ESCC.

Where do FDA and PMDA reviews stand?

Takeda says the U.S. NDA is under FDA priority review with Breakthrough Therapy designation, and the Japanese filing is under review with Sakigake designation, with more submissions planned through the year. A February 2026 Business Wire notice of FDA NDA acceptance and priority review set the U.S. procedural clock; PDUFA timing should be tracked from that review clock rather than inferred here. Japan’s Sakigake pathway is a parallel APAC signal for Takeda’s home-market strategy — useful context alongside PMDA Sakigake designation pathways.

Commercially, China-first approval for a global first-in-class asset inverts the usual US/EU-then-China sequence. For APAC market access teams, watch NRDL negotiation timing, specialist sleep-center uptake, and how diagnostic delay messaging shapes patient-finding programs. For pipeline watchers, Takeda’s follow-on OX2R agonist TAK-360 is positioned for NT2 and idiopathic hypersomnia — a franchise play if Orzeyful establishes the class in China.

What should BD and medical affairs track next?

Near-term watch items: (1) Chinese label text and dosing versus the 1 mg / 2 mg BID trial arms; (2) post-marketing safety for insomnia and urinary AEs in real-world NT1 clinics; (3) FDA and PMDA decision dates; (4) competitor OX2R programs and whether China pricing sets an anchor for other markets. None of those are decided in the July 22 release — only the marketing authorization and the pivotal-trial framing are.

Bottom line for APAC intelligence desks: Orzeyful’s NMPA clearance puts China ahead of the U.S. and Japan on the first approved OX2R agonist for NT1, with a 273-patient Phase 3 backbone (168 + 105) and a clear next-catalyst map into FDA priority review and Sakigake.

Frequently Asked Questions